资源 » 参考数据库 » 客户发表文献

至今，GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次，处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果，再次证明GenScript 有能力帮助业内科学家Make research easy.

Therapeutic Targeting of Golgi Phosphoprotein 2 (GOLPH2) with Armed Antibodies: A Preclinical Study of Anti-GOLPH2 Antibody Drug Conjugates in Lung and Colorectal Cancer Models of Patient Derived Xenografts (PDX).

Target Oncol. 2019;

Liewen Heike，Markuly Norbert，L?ubli Heinz，Liu Yang，Matter Matthias S，Liewen Nora，Renner Christoph，Zippelius Alfred，Stenner F

Products/Services Used	Details	Operation
Nucleic Acid Purification & Analysis	The sequence of the light chain variable region (VRLC) was supplemented at the 5′ end by an immunoglobulin G signal peptide sequence (ATGGACTTCCAGGTCCAGATTATC TCCTTCCTGCTGATTTCTGCCTCTGTGATAATGAGT AGGGGA) and a kappa light chain (kLC) sequence at the 3′ end site, synthesized by Genscript (Piscataway, NJ, USA) and cloned into the HindIII/XbaI sites of the expression vector pcDNA3.	Get A Quote

摘要

Golgi phosphoprotein 2 (GOLPH2) has been shown to be involved in chronic inflammatory processes and carcinogenesis. GOLPH2 is prominently overexpressed in hepatocellular carcinoma， melanoma， glioblastoma， prostate， lung， and colorectal cancer. With a low and tightly regulated expression in non-malignant tissues， GOLPH2 has been proposed as an attractive target for cancer therapy. However， GOLPH2 is predominantly located intracellularly and when situated outside of the cell it is proteolytically cleaved and shed from the cell surface. Until now， GOLPH2 has been regarded as an "undruggable" target.